Ben Bronstein - 30 Jun 2023 Form 4 Insider Report for Aldeyra Therapeutics, Inc. (ALDX)

Role
Director
Signature
/s/ Ben Bronstein
Issuer symbol
ALDX
Transactions as of
30 Jun 2023
Transactions value $
$0
Form type
4
Filing time
05 Jul 2023, 17:34:59 UTC
Previous filing
29 Jun 2023
Next filing
06 Jun 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALDX Stock Option (Right to Buy) Award $0 +21.2K $0.00 21.2K 30 Jun 2023 Common Stock 21.2K $8.39 Direct F1
transaction ALDX Stock Option (Right to Buy) Award $0 +1.37K $0.00 1.37K 30 Jun 2023 Common Stock 1.37K $8.39 Direct F2
transaction ALDX Stock Option (Right to Buy) Award $0 +1.46K $0.00 1.46K 30 Jun 2023 Common Stock 1.46K $8.39 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date.
F2 Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date.
F3 Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Nominating/Corporate Governance Committee of the Board of Directors of the Issuer through the applicable vesting date.